Ruham Alshiekh Nasany

Dr. Ruham Alshiekh Nasany

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2023 in Current Neurology and Neuroscience Reports
Verified
Journal Article
Open access
PDF file
RNRuham Alshiekh Nasany
Ruham Alshiekh Nasany
MFMacarena De la Fuente
Macarena De la Fuente
Purpose of Review: Isocitrate dehydrogenase (IDH) mutant gliomas are a distinct type of primary brain tumors with unique characteristics, behavior, and disease outcomes. This article provides a review of standard of care treatment options and innovative, therapeutic approaches that are currently under investigation for these tumors. Recent Findings: Extensive pre-clinical data and a variety of clinical studies support targeting IDH mutations in glioma using different mechanisms, which include direct inhibition and immunotherapies that target metabolic and epigenomic vulnerabilities caused by these mutations. Summary: IDH mutations have been recognized as an oncogenic driver in gliomas for more than a decade and as a positive prognostic factor influencing the research for new therapeutic methods including IDH inhibitors, DNA repair inhibitors, and immunotherapy.

4 February 2016 in Acta Haematologica
Verified
Journal Article
Closed access
RNRuham Alshiekh Nasany
Ruham Alshiekh Nasany
DDDan Douer
Dan Douer
Introduction: Similar to pediatric regimens, multiple doses of L-asparaginase (PEG-Asp) are being increasingly used in adults with newly diagnosed acute lymphoblastic leukemia (ALL) with promising results. One of the most common side effects of the drug in adults is high-grade hyperbilirubinemia and transaminitis. Despite being almost always reversible and may not recur, clinicians may still be reluctant to continue with PEG-Asp in patients with liver toxicity, losing the benefit from multiple doses of the drug. Case Report: We describe a case of adult ALL who developed PEG-Asp-related high grade liver toxicity. The rising hyperbilirubinemia and transaminitis rapidly and permanently reversed using the amino-acid derivative L-carnitine. This case goes in line with similar observations in animal models and humans. Conclusion:L-Carnitine may show therapeutic benefit in PEG-Asp-related hepatotoxicity and should be considered in clinical trials of the drug.

20 December 2016 in Cytoskeleton
Verified
Journal Article
Closed access
PDF file
DDDipak K. Dube
Dipak K. Dube
SDSyamalima Dube
Syamalima Dube
LALynn Abbott
Lynn Abbott
JWJushuo Wang
Jushuo Wang
YFYingli Fan
Yingli Fan
JSJoseph W. Sanger
Joseph W. Sanger

9 November 2016 in Clinical Case Reports
Verified
Journal Article
Open access
PDF file
RNRuham Alshiekh Nasany
Ruham Alshiekh Nasany
AZAwss Zidan
Awss Zidan
CMCarmen Martinez
Carmen Martinez
Key Clinical Message: New‐generation tyrosine kinase inhibitors (TKI) are promising agents for the treatment of chronic myeloid leukemia (CML), but the linkage to vascular diseases warrants a special attention from treating physicians, as it may carry major morbidity and mortality.

15 September 2016 in Molecular Biology International
Verified
Journal Article
Open access
PDF file
DDDipak K. Dube
Dipak K. Dube
SDSyamalima Dube
Syamalima Dube
LALynn Abbott
Lynn Abbott
RNRuham Alshiekh Nasany
Ruham Alshiekh Nasany
CMCharles Mitschow
Charles Mitschow
BPBernard Poiesz
Bernard Poiesz
In mammals, tropomyosin is encoded by four known TPM genes (TPM1, TPM2, TPM3, and TPM4) each of which can generate a number of TPM isoforms via alternative splicing and/or using alternate promoters. In humans, the sarcomeric isoform(s) of each of the TPM genes, except for the TPM4, have been known for a long time. Recently, on the basis of computational analyses of the human genome sequence, the predicted sequence of TPM4αhas been posted in GenBank. We designed primer-pairs for RT-PCR and showed the expression of the transcripts of TPM4αand a novel isoform TPM4δin human heart and skeletal muscle. qRT-PCR shows that the relative expression of TPM4αand TPM4δis higher in human cardiac muscle. Western blot analyses using CH1 monoclonal antibodies show the absence of the expression of TPM4δprotein (~28 kDa) in human heart muscle. 2D western blot analyses with the same antibody show the expression of at least nine distinct tropomyosin molecules with a mass ~32 kD and above in adult heart. By Mass spectrometry, we determined the amino acid sequences of the extracted proteins from these spots. Spot “G” reveals the putative expression of TPM4αalong with TPM1αprotein in human adult heart.

8 June 2021 in Neurology
Verified
Journal Article
Open access
PDF file
JFJasmine Francis
Jasmine Francis
YGY. Pierre Gobin
Y. Pierre Gobin
RNRuham Alshiekh Nasany
Ruham Alshiekh Nasany
JKJared Knopman
Jared Knopman
GUGary A. Ulaner
Gary A. Ulaner
EDEli L. Diamond
Eli L. Diamond